Evaluation of Tacrolimus (Prograf®) intraportal infusion during the implantation and the protective effect on ischemia-reperfusion injury in orthotopic liver transplant recipients - single center study
- Conditions
- The effect of Tacrolimus (Prograf®) during the implantation on ischemia-reperfusion injury in orthotopic liver transplant recipients
- Registration Number
- EUCTR2007-006049-41-AT
- Lead Sponsor
- Medizinische Universität Wien; Univ.Klin.f. Chirurgie; Klin. Abtlg. f. Transplantation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 26
Inclusion criteria
- Patients, who are listed on the liver transplant-waiting list at the Vienna General Hospital and who fulfil the clinical requirements (local allocation)
- Written informed consent
- Age > 18
- First transplantation
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion criteria
- Fulminant failure of the liver
- Liver-Living donor recipients
- Multiorgantransplantation or retransplantation
- ABO incompatible donor organ recipients
- pregnant or nursing women
- Allergy/Intolerance to antimetaboliten, HCO-60, EL Cremophor or similar compounds
Steroids or Macrolid antibiotics
- HIV-positive donors or recipients
- Participants of another clinical study
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method